Pharmaresearch Bio파마리서치바이오
217950 · KONEX · ₩217950 · 파마리서치바이오
₩29,250▲ ₩50 (0.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 70.1% | 70.1% | 64.4% | 61.7% | 54.5% | 50.4% |
| Operating margin | 44.2% | 44.2% | 33.2% | 31.1% | 20.1% | 24.8% |
| Net margin | 39.7% | 39.7% | 39.0% | 11.5% | 59.3% | 21.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +19.1% | +19.1% | +30.3% | +60.2% | +18.2% | — |
| Operating income growth | +58.4% | +58.4% | +39.3% | +148.1% | −4.4% | — |
| Net income growth | +21.3% | +21.3% | +340.3% | −68.9% | +221.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 24.5% | 24.5% | 26.3% | 8.2% | 41.2% | 16.4% |
| Return on assets | 12.9% | 12.9% | 13.5% | 3.8% | 13.7% | 4.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 81.4% | 81.4% | 101.9% | 85.8% | 167.9% | 252.7% |
| Net debt to equity | −16.6% | −16.6% | −31.9% | −54.7% | −84.6% | −139.8% |
| Current ratio | 109.0% | 109.0% | 116.6% | 159.1% | 219.2% | 169.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Pharmaresearch Bio / 파마리서치바이오 / 217950 / KRX:217950
Source: KRX statistical information